The reduction in price target by a reputable analyst like Mara Goldstein from Mizuho could lead to a negative short-term sentiment among investors, as it suggests a lower expected future price for Leap Therapeutics. However, the maintenance of a Buy rating indicates a continued positive outlook on the company's fundamentals, which might mitigate some of the negative impact.